Stanford University: Lymphoma, Non-Hodgkin trials

The registry lists 21 Lymphoma, Non-Hodgkin studies with Stanford University as lead sponsor. 3 are open to participants now and 8 have results posted.

Phase 1 6Phase 2 9No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelRecruitingNCT05794958Phase 1
• ID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeRecruitingNCT02848274
• Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's DiseaseRecruitingNCT00398177
• Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
• Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T CellCompletedNCT01660607Phase 1/2Results posted
• Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCTTerminatedNCT01220297Phase 2Results posted
• Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell LymphomaCompletedNCT00896493Phase 2Results posted
• Study of Bexxar <Tositumomab> Combined With External Beam Radiation TherapyTerminatedNCT00490490Phase 2Results posted
• Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCTTerminatedNCT00482053Phase 2Results posted
• Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's LymphomaTerminatedNCT00481832Phase 2Results posted
• Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's LymphomaCompletedNCT00225212Phase 2Results posted
• Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at StanfordWithdrawnNCT05416554Not applicable
• Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse EventsCompletedNCT05123001
• Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
• Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host DiseaseCompletedNCT01155817Phase 1
• Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody TreatmentCompletedNCT00398372Not applicable
• Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCTCompletedNCT00350181Phase 2
• 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHLCompletedNCT00186589Phase 1
• High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's LymphomaCompletedNCT00186394Phase 2
• Enrichment & Purging of Stem Cells in Non-Hodgkin's LymphomaCompletedNCT00186355Not applicable
• Allo BMT in Advanced Leukemia or High Grade LymphomaCompletedNCT00186290Not applicable